YARDLEY, Pa.--(BUSINESS WIRE)--Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application ...
Xhance was evaluated in five trials enrolling >1,500 adults. Optinose announced that the Food and Drug Administration (FDA) has approved Xhance (fluticasone propionate) Nasal Spray for the treatment ...
Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose ...
The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...
YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...
Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other medications, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback